慢性嗜酸性粒细胞白血病-非特指型:临床特征、基因组学见解与治疗策略
本文综述慢性嗜酸性粒细胞白血病-非特指型(CEL-NOS)的临床特征、诊断方法、遗传学进展与治疗挑战。CEL-NOS缺乏特异性遗传驱动因素,治疗选择有限、预后差且存在急性白血病转化风险;异基因移植是唯一可能治愈的手段,但移植后5年生存率仅三分之一。
要点
- CEL-NOS为罕见骨髓增殖性肿瘤,表现为持续性克隆性嗜酸性粒细胞增多,缺乏特异性遗传驱动因素。
- 部分既往归类为特发性高嗜酸性粒细胞综合征的病例,经分子技术可明确克隆性。
- 治疗选择有限、预后差且有急性白血病转化风险;移植是唯一可能治愈手段,但移植后5年生存率仅三分之一。
核心结论
- CEL-NOS缺乏特异性遗传驱动因素和干预靶点,治疗选择有限、预后差且存在急性白血病转化风险,是重大治疗挑战。
- 异基因移植是唯一可能治愈的治疗,但患者常为老年且合并症多,移植可及性受限,移植后预后仍差,5年生存率仅三分之一。
研究设计与样本
- 本文为综述,旨在整合CEL-NOS的诊断方法、遗传学进展与治疗挑战,并指出未来研究的关键领域。
主要发现
- 遗传学进展细化了诊断标准,识别出伴特定细胞遗传学和分子异常、现归类为伴嗜酸性粒细胞增多和酪氨酸激酶基因融合的髓系/淋系肿瘤的CEL亚型,这些亚型可能受益于靶向治疗。
- CEL-NOS缺乏特异性遗传驱动因素和阻止白血病发生的干预靶点。
- 分子技术使相当比例原本归类为特发性高嗜酸性粒细胞综合征的病例得以明确克隆性。
- 患者常为老年且合并症多,移植可及性受限;移植后5年生存率仅三分之一。
- 类固醇、细胞减灭治疗和免疫调节治疗等其他疗法反应有限且短暂,并伴显著副作用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic eosinophilia leukaemia-not otherwise specified (CEL-NOS) is a rare myeloproliferative neoplasm characterized by persistent clonal hypereosinophilia. Recent advances in genetics have refined diagnostic criteria, leading to the identification of CEL subtypes with specific cytogenetic and molecular abnormalities now classified as myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions, which may benefit from targeted therapies. In contrast, CEL-NOS lacks specific genetic drivers and intervention points to halt leukemogenesis. Molecular techniques have also enabled the definition of clonality in a considerable percentage of cases otherwise classified as idiopathic hypereosinophilic syndrome. CEL-NOS poses a significant therapeutic challenge due to limited treatment options, poor prognosis and the risk of progression to acute leukaemia. Patients, often elderly and with comorbidities, face restricted access to transplantation, the only potentially curative treatment. Unfortunately, the prognosis remains poor even post-transplant, with a 5-year survival rate of only one-third of patients. Other therapies, including steroids, cytoreductive and immunomodulatory treatments, offer limited and temporary responses with significant side effects. This review aims to consolidate current knowledge on CEL-NOS, covering diagnostic approaches, genetic advancements and therapeutic challenges. It seeks to provide a comprehensive overview and highlight critical areas for future research.
引用
- Costa A, Scalzulli E, Breccia M, et al. Chronic eosinophilic leukaemia-Not otherwise specified: Clinical features, genomic insight and therapeutic strategies. Br J Haematol. 2024. PMID: 39600052. doi:10.1111/bjh.19921
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。